<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMJ Case Rep</journal-id><journal-id journal-id-type="iso-abbrev">BMJ Case Rep</journal-id><journal-id journal-id-type="hwp">bmjcr</journal-id><journal-id journal-id-type="publisher-id">bmjcasereports</journal-id><journal-title-group><journal-title>BMJ Case Reports</journal-title></journal-title-group><issn pub-type="epub">1757-790X</issn><publisher><publisher-name>BMJ Publishing Group</publisher-name><publisher-loc>BMA House, Tavistock Square, London, WC1H 9JR</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">31911409</article-id><article-id pub-id-type="pmc">6954780</article-id><article-id pub-id-type="publisher-id">bcr-2019-231844</article-id><article-id pub-id-type="doi">10.1136/bcr-2019-231844</article-id><article-categories><subj-group subj-group-type="heading"><subject>Rare Disease</subject></subj-group><subj-group subj-group-type="hwp-journal-coll"><subject>1506</subject><subject>1523</subject><subject>495</subject><subject>498</subject><subject>504</subject></subj-group><series-title>Case report</series-title></article-categories><title-group><article-title>HHV-8-negative multicentric Castleman disease presenting as a crescentic immune complexes membranoproliferative glomerulonephritis</article-title></title-group><contrib-group><contrib id="author-71381939" contrib-type="author" corresp="yes"><name><surname>Nunes</surname><given-names>Maria Brito</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib id="author-71382733" contrib-type="author"><name><surname>Rotman</surname><given-names>Samuel</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib id="author-71382812" contrib-type="author"><name><surname>Duss</surname><given-names>Francois-Regis</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib id="author-71382840" contrib-type="author"><name><surname>Halfon</surname><given-names>Matthieu</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib></contrib-group><aff id="aff1">
<label>1</label>
<institution content-type="department">Internal Medicine</institution>, <institution>Centre Hospitalier Universitaire Vaudois</institution>, <addr-line content-type="city">Lausanne</addr-line>, <country>Switzerland</country>
</aff><aff id="aff2">
<label>2</label>
<institution content-type="department">Institute of Pathology</institution>, <institution>Centre Hospitalier Universitaire Vaudois</institution>, <addr-line content-type="city">Lausanne</addr-line>, <country>Switzerland</country>
</aff><aff id="aff3">
<label>3</label>
<institution content-type="department">Nephrology</institution>, <institution>Centre Hospitalier Universitaire Vaudois</institution>, <addr-line content-type="city">Lausanne</addr-line>, <country>Switzerland</country>
</aff><author-notes><corresp><label>Correspondence to</label> Dr Maria Brito Nunes; <email>lucilia.b.nunes@gmail.com</email></corresp></author-notes><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>6</day><month>1</month><year>2020</year></pub-date><pub-date pub-type="pmc-release"><day>6</day><month>1</month><year>2020</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>13</volume><issue>1</issue><elocation-id>e231844</elocation-id><history><date date-type="accepted"><day>18</day><month>11</month><year>2019</year></date></history><permissions><copyright-statement>&#x000a9; BMJ Publishing Group Limited 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</copyright-statement><copyright-year>2020</copyright-year><license license-type="open-access"><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2020-06-01">http://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:&#x000a0;<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="bcr-2019-231844.pdf"/><abstract><p>Multicentric Castleman disease is a rare polyclonal lymphoproliferative disorder mainly associated with two renal manifestations: thrombotic microangiopathy and amyloidosis. Nevertheless, we report here a case of human herpes virus-8 negative multicentric Castleman disease with membranous proliferative glomerulonephritis and extracapillary proliferation. A patient was successfully treated with corticosteroids, anti-CD20 and cyclophosphamide therapy.</p></abstract><kwd-group><kwd>acute renal failure</kwd><kwd>proteinurea</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>special-feature</meta-name><meta-value>unlocked</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1"><title>Background</title><p>Castleman disease is a rare<xref rid="R1" ref-type="bibr">1 2</xref> polyclonal lymphoproliferative disorder characterised by three histological patterns: hyaline vascular, plasma cell and plasmablastic.<xref rid="R2" ref-type="bibr">2</xref> Clinical presentation is heterogeneous<xref rid="R2" ref-type="bibr">2</xref> and classified into unicentric or multicentric disease.<xref rid="R1" ref-type="bibr">1 2</xref> Unicentric Castleman disease is the most frequent type.<xref rid="R3" ref-type="bibr">3</xref> It involves a single lymph nodal region, and symptoms are mainly due to local lymph node enlargement.<xref rid="R3" ref-type="bibr">3</xref> Its surgical resection is curative.<xref rid="R3" ref-type="bibr">3</xref> By contrast, multicentric Castleman disease involves multiple lymph node areas.<xref rid="R4" ref-type="bibr">4&#x02013;6</xref> It is subclassified into the human herpes virus-8 (HHV-8) related or not.<xref rid="R5" ref-type="bibr">5&#x02013;7</xref> Multicentric Castleman disease is a severe multisystemic disease, with non-specific symptoms such as lymphadenopathy, fever, weight loss, fatigue, oedema and ascites.<xref rid="R3" ref-type="bibr">3 8</xref> The high level of cytokines production, notably interleukin-6 (IL-6),<xref rid="R7" ref-type="bibr">7</xref> can affect each system and eventually lead to multiorgan failure.<xref rid="R6" ref-type="bibr">6</xref> IL-6 pathway is the therapeutic target.<xref rid="R3" ref-type="bibr">3 5 9 10</xref> Nevertheless, recurrence is frequent and prognosis poor.<xref rid="R10" ref-type="bibr">10</xref> Renal involvement is also common<xref rid="R11" ref-type="bibr">11</xref> and various histological patterns have been described. A membranous proliferative glomerulonephritis has been previously reported, nevertheless extracapillary proliferation has not been described yet.</p></sec><sec id="s2"><title>Case presentation</title><p>A 48-year-old man from the Middle East presented to our hospital because of night sweats, lower extremity oedema and a weight loss of 12&#x02009;kg in 3 months.</p><p>He had a medical history of dyslipidaemia, severe obesity (body mass index of 35&#x02009;kg/m<sup>2</sup>) and 25 pack-year of previous smoking. 2.5 months before admission, he was admitted to another hospital because of an acute left limb pain. A multisegmental artery occlusion of the limb was then diagnosed which justified an anticoagulation by vitamin K antagonist.</p><p>The patient had no other complaints. Except for increased blood pressure and bilateral pitting oedema, clinical examination was normal.</p></sec><sec id="s3"><title>Investigations</title><p>Blood test showed acute kidney injury (creatinaemia 200&#x02009;&#x000b5;mol/L) with hypoalbuminaemia (26&#x02009;g/L), an elevated sedimentation rate (&#x0003e;100&#x02009;mm/hour) and elevated CRP (90&#x02009;mg/L). Urinalysis showed erythrocytes cast. Twenty-four&#x02009;hour urine protein excretion was 9.24&#x02009;g/day. Finally, a kidney ultrasound with Doppler showed no anomaly. Because of the nephritic syndrome, a renal biopsy was performed. On microscopic examination (23 glomeruli), we observed a membranous proliferative pattern with the presence of a crescent (<xref ref-type="fig" rid="F1 F2">figures 1 and 2</xref>). Immunofluorescence was positive for IgA (+/&#x02013;, rare deposits), IgG (++), IgM (+/&#x02013;), C3 (+++), C1q (++) and C5b9 (+/&#x02013;) deposits (full house), but kappa and lambda light chains were negative (<xref ref-type="fig" rid="F3 F4">figures 3 and 4</xref>). The electron microscopy disclosed the presence of subendothelial and subepithelial deposits. We estimated between 20% and 30% of fibrosis. At this stage, a crescentic immune complex glomerulonephritis with a membranoproliferative pattern was suspected.</p><fig id="F1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Renal biopsy showed an extracapillary proliferation with cellular crescents (FAOG, &#x000d7;400). FAOG, femtosecond amplifying optical gate.</p></caption><graphic xlink:href="bcr-2019-231844f01"/></fig><fig id="F2" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Renal biopsy showed a membranoproliferative glomerulonephritis pattern: flocculi are lobulated with a duplication of the membrane. Endocapillary and extracapillay proliferations were also observed.</p></caption><graphic xlink:href="bcr-2019-231844f02"/></fig><fig id="F3" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Immunofluorescence: IgG deposits were observed within mesangium and membranes of glomeruli (&#x000d7;400).</p></caption><graphic xlink:href="bcr-2019-231844f03"/></fig><fig id="F4" orientation="portrait" position="float"><label>Figure 4</label><caption><p>Immunofluorescence: C3 deposits were observed within mesangium and membranes of glomeruli (&#x000d7;200).</p></caption><graphic xlink:href="bcr-2019-231844f04"/></fig><p>The immunological workup was negative: absence of monoclonal spike but a polyclonal hypergammaglobulinaemia on the immunofixation; negative antinuclear antibodies and antineutrophil cytoplasmic antibody, normal C3 and C4 as well as the absence of cryoglobulinaemia and antiphospholipid antibodies. An exhaustive infectious workup was also done with negative polymerase chain reaction (PCR) for cytomegalovirus (CMV), Epstein-Barr virus (EBV), hepatitis B, C, HIV and HHV-8, negative bacterial serologies for leptospirosis, Brucella spp, <italic>Borrelia burgdorferi</italic>, <italic>Coxiella burnetii</italic>, <italic>Bartonella henselae</italic>, syphilis, as well as toxoplasma. Finally, interferon-gamma release assay was negative as well as urine culture for mycobacteria. Blood culture was also sterile; beta-d-glucan in the blood was negative. Although, a high level of IL-6 (18.5&#x02009;&#x000b5;g/L, n&#x0003c;1&#x02009;&#x000b5;g/L) prompted us to search for an inflammatory process. A 2-fludeoxyglucose (2-FDG) positron emission tomography scan revealed supra and subdiaphragmatic hypercaptive adenopathies, a mediastinal mass hypercaption, and a splenic abnormal FDG uptake. A left axillary lymph node resection was performed. Pathology determined a Castleman-like pattern with hyperplasic adenopathy, associated with follicular hyperplasia, interfollicular expansion and significant polytypic plasma cells and circularly capillary penetrated some germinal centres. There was no evidence of lymphoma. HHV-8 and EBV immunohistochemistry were negative. Moreover, fewer than 10% of plasma cells were IgG4 positive.</p></sec><sec id="s4"><title>Differential diagnosis</title><p>We concluded that this patient suffered from HHV-8 negative multicentric Castleman&#x02019;s disease. Treatment was initiated with corticosteroids, anti-CD 20 therapy with rituximab and cyclophosphamide.</p><p>In our case, due to the absence of monotypic deposits, a monoclonal gammopathy of renal significance is easily excluded. In the absence of a predominant C3 deposits, a C3 glomerulopathy seems unlikely. The full-house pattern points to two hypotheses: lupus nephritis or an infectious glomerulonephritis. In the absence of signs or symptoms of lupus and antinuclear antibodies, a diagnosis of lupus nephritis is excluded. Finally, an infection-related glomerulonephritis is unlikely because of the negativity of the full infectious workup. Moreover, improvement of the clinical status under a strong immunosuppressive therapy does not suggest an infectious process and supports that Castleman disease is the only possible aetiology.</p><p>Therefore, we concluded that the crescentic immune complex glomerulonephritis with a membranoproliferative pattern was secondary to multicentric Castleman disease.</p></sec><sec id="s5"><title>Outcome and follow-up</title><p>The patient quickly improved: a few days after corticoids administration the fever and inflammatory markers decreased. A 2-FDG positron emission tomography scan was repeated 3 months later, which showed regression of the lymphadenopathies without hypercaption. In parallel, proteinuria level decreased completely after 2 months and renal function improved slowly. One year later, creatinaemia was 144&#x02009;&#x000b5;mol/L.</p></sec><sec sec-type="discussion" id="s6"><title>Discussion</title><p>Clinicians investigating membranoproliferative glomerulonephritis must do a comprehensive search to find the right aetiology and the nature of the immune deposit is the principal clue.</p><p>Up to 54% of multisystemic Castleman disease, mostly in plasma cell or mixed cellular type, are associated with nephropathy, defined as haematuria, proteinuria or renal insufficiency.<xref rid="R11" ref-type="bibr">11&#x02013;14</xref> The two main histological patterns are thrombotic microangiopathy (60%) and amyloidosis (20%).<xref rid="R15" ref-type="bibr">15 16</xref> Those histological patterns could be explained by the dysregulation of IL-6 production and vascular endothelial growth factors in the lymph node mantle.<xref rid="R15" ref-type="bibr">15 17&#x02013;19</xref> Indeed, IL-6 proinflammatory cytokine stimulates the precursor of the AA protein and vascular endothelial growth factors, leading to thrombotic microangiopathy.<xref rid="R20" ref-type="bibr">20 21</xref>
</p><p>Nevertheless, our patient had proliferative immune complex glomerulonephritis. We hypothesised that the high level of IL-6 promoted B cell activation, which in turn induced immune complexes. Those immune complexes get &#x02018;trapped&#x02019; in the subendothelial space of the glomeruli and lead to a proliferative glomerulonephritis.</p><p>In the recent years, new treatments for HHV-8-negative/idiopathic multicentric Castleman disease (iMCD) have been developed, such as anti-IL-6 monoclonal antibody (anti-IL-6 mAb) siltuximab or tocilizumab.<xref rid="R9" ref-type="bibr">9 22</xref> They are now considered as preferred first-line therapy,<xref rid="R22" ref-type="bibr">22</xref> sometimes in association with corticosteroid.<xref rid="R22" ref-type="bibr">22</xref> Anti-CD20 mAb (rituximab) is an alternative to anti-IL-6 mAb in the case of non-severe iMCD (defined as a good performance status without organ dysfunction), however, with a lower proportion of complete responses and progression-free survival compared with siltuximab.<xref rid="R23" ref-type="bibr">23</xref>
</p><boxed-text id="BX2" position="float" orientation="portrait"><caption><title>Patient&#x02019;s perspective</title></caption><p>The experience of sickness, the lose of strength, especially when you are a man of 48 years old, is hard to accept. I did not understood what was wrong with my body. I was afraid to die. During hospitalisation doctors had to performed a lot of tests to find out why I was losing weight and why my kidneys were failing. Then, I was shocked to learn that I had a rare disease called Castleman disease. I asked myself several times : why me? With the help of the medical team I understood better my disease and I started a treatment. At the end, I feel lucky because the treatment improved my condition and my kidneys function, and I have the support of my family. Currently I have almost a normal life.</p></boxed-text><boxed-text id="BX1" position="float" orientation="portrait"><caption><title>Learning points</title></caption><list list-type="bullet"><list-item><p>Castleman disease is a rare non-neoplasic lymphoproliferative disorder characterised by various renal manifestations with two main histological patterns: thrombotic microangiopathy and amyloidosis.</p></list-item><list-item><p>Castleman disease is also a possible aetiology for a proliferative immune complex glomerulonephritis after exclusion of other frequent causes such as infection-related glomerulonephritis.</p></list-item><list-item><p>The anti-interleukin-6 monoclonal antibody, siltuximab or tocilizumab are considered as first-line treatment for human herpes virus-8-negative/idiopathic multicentric Castleman disease.</p></list-item></list></boxed-text></sec></body><back><fn-group><fn fn-type="other"><p><bold>Contributors:</bold> MBN and F-RD conceived the design of the article, the background and clinical presentation; SR described and analysed the biopsy findings and selected the pictures. MH wrote the differential diagnosis and follow-up. All the authors participated to the discussion. SR, F-RD and MH revised the article.</p></fn><fn fn-type="other"><p><bold>Funding:</bold> The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.</p></fn><fn fn-type="COI-statement"><p><bold>Competing interests:</bold> None declared.</p></fn><fn fn-type="other"><p><bold>Patient consent for publication:</bold> Obtained.</p></fn><fn fn-type="other"><p><bold>Provenance and peer review:</bold> Not commissioned; externally peer reviewed.</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>1</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Blute</surname><given-names>ML</given-names></name>, <name name-style="western"><surname>Abramson</surname><given-names>JS</given-names></name>, <name name-style="western"><surname>Cronin</surname><given-names>KC</given-names></name>, <etal>et al</etal></person-group>
<article-title>Case 5-2017. A 19-year-old man with hematuria and a retroperitoneal mass.</article-title>. <source>N Engl J Med</source>
<year>2017</year>;<volume>376</volume>:<fpage>684</fpage>&#x02013;<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMcpc1610100</pub-id>
<pub-id pub-id-type="pmid">28199810</pub-id></mixed-citation></ref><ref id="R2"><label>2</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>JP</given-names></name>, <name name-style="western"><surname>Shen</surname><given-names>XF</given-names></name>, <name name-style="western"><surname>JF</surname><given-names>D</given-names></name>, <etal>et al</etal></person-group>
<article-title>A retrospective study of 34 patients with unicentric and multicentric Castleman&#x02019;s disease: experience from a single institution</article-title>. <source>Oncol Lett</source>
<year>2018</year>;<volume>15</volume>:<fpage>2407</fpage>&#x02013;<lpage>12</lpage>.<pub-id pub-id-type="pmid">29434951</pub-id></mixed-citation></ref><ref id="R3"><label>3</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>van Rhee</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Stone</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Szmania</surname><given-names>S</given-names></name>, <etal>et al</etal></person-group>
<article-title>Castleman disease in the 21st century: an update on diagnosis, assessment, and therapy</article-title>. <source>Clin Adv Hematol Oncol</source>
<year>2010</year>;<volume>8</volume>:<fpage>486</fpage>&#x02013;<lpage>98</lpage>.<pub-id pub-id-type="pmid">20864917</pub-id></mixed-citation></ref><ref id="R4"><label>4</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Oksenhendler</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Boutboul</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Fajgenbaum</surname><given-names>D</given-names></name>, <etal>et al</etal></person-group>
<article-title>The full spectrum of Castleman disease: 273 patients studied over 20&#x000a0;years</article-title>. <source>Br J Haematol</source>
<year>2018</year>;<volume>180</volume>:<fpage>206</fpage>&#x02013;<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1111/bjh.15019</pub-id>
<pub-id pub-id-type="pmid">29143319</pub-id></mixed-citation></ref><ref id="R5"><label>5</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Fajgenbaum</surname><given-names>DC</given-names></name>, <name name-style="western"><surname>Ruth</surname><given-names>JR</given-names></name>, <name name-style="western"><surname>Kelleher</surname><given-names>D</given-names></name>, <etal>et al</etal></person-group>
<article-title>The collaborative network approach: a new framework to accelerate Castleman's disease and other rare disease research</article-title>. <source>The Lancet Haematology</source>
<year>2016</year>;<volume>3</volume>:<fpage>e150</fpage>&#x02013;<lpage>2</lpage>. <pub-id pub-id-type="doi">10.1016/S2352-3026(16)00007-7</pub-id>
<pub-id pub-id-type="pmid">27063967</pub-id></mixed-citation></ref><ref id="R6"><label>6</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Fajgenbaum</surname><given-names>DC</given-names></name>, <name name-style="western"><surname>Uldrick</surname><given-names>TS</given-names></name>, <name name-style="western"><surname>Bagg</surname><given-names>A</given-names></name>, <etal>et al</etal></person-group>
<article-title>International, evidence-based consensus diagnostic criteria for HHV-8&#x02013;negative/idiopathic multicentric Castleman disease</article-title>. <source>Blood</source>
<year>2017</year>;<volume>129</volume>:<fpage>1646</fpage>&#x02013;<lpage>57</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2016-10-746933</pub-id>
<pub-id pub-id-type="pmid">28087540</pub-id></mixed-citation></ref><ref id="R7"><label>7</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Fajgenbaum</surname><given-names>DC</given-names></name>, <name name-style="western"><surname>Shilling</surname><given-names>D</given-names></name></person-group>
<article-title>Castleman disease pathogenesis</article-title>. <source>Hematol Oncol Clin North Am</source>
<year>2018</year>;<volume>32</volume>:<fpage>11</fpage>&#x02013;<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1016/j.hoc.2017.09.002</pub-id>
<pub-id pub-id-type="pmid">29157613</pub-id></mixed-citation></ref><ref id="R8"><label>8</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>AY</given-names></name>, <name name-style="western"><surname>Nabel</surname><given-names>CS</given-names></name>, <name name-style="western"><surname>Finkelman</surname><given-names>BS</given-names></name>, <etal>et al</etal></person-group>
<article-title>Idiopathic multicentric Castleman's disease: a systematic literature review</article-title>. <source>Lancet Haematol</source>
<year>2016</year>;<volume>3</volume>:<fpage>e163</fpage>&#x02013;<lpage>75</lpage>. <pub-id pub-id-type="doi">10.1016/S2352-3026(16)00006-5</pub-id>
<pub-id pub-id-type="pmid">27063975</pub-id></mixed-citation></ref><ref id="R9"><label>9</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>van Rhee</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Wong</surname><given-names>RS</given-names></name>, <name name-style="western"><surname>Munshi</surname><given-names>N</given-names></name>, <etal>et al</etal></person-group>
<article-title>Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial</article-title>. <source>Lancet Oncol</source>
<year>2014</year>;<volume>15</volume>:<fpage>966</fpage>&#x02013;<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1016/S1470-2045(14)70319-5</pub-id>
<pub-id pub-id-type="pmid">25042199</pub-id></mixed-citation></ref><ref id="R10"><label>10</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Dispenzieri</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Armitage</surname><given-names>JO</given-names></name>, <name name-style="western"><surname>Loe</surname><given-names>MJ</given-names></name>, <etal>et al</etal></person-group>
<article-title>The clinical spectrum of Castleman's disease</article-title>. <source>Am J Hematol</source>
<year>2012</year>;<volume>87</volume>:<fpage>997</fpage>&#x02013;<lpage>1002</lpage>. <pub-id pub-id-type="doi">10.1002/ajh.23291</pub-id>
<pub-id pub-id-type="pmid">22791417</pub-id></mixed-citation></ref><ref id="R11"><label>11</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>El Karoui</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Vuiblet</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Dion</surname><given-names>D</given-names></name>, <etal>et al</etal></person-group>
<article-title>Renal involvement in Castleman disease</article-title>. <source>Nephrol Dial Transplant</source>
<year>2011</year>;<volume>26</volume>:<fpage>599</fpage>&#x02013;<lpage>609</lpage>. <pub-id pub-id-type="doi">10.1093/ndt/gfq427</pub-id>
<pub-id pub-id-type="pmid">20656751</pub-id></mixed-citation></ref><ref id="R12"><label>12</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Lv</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Dong</surname><given-names>Y</given-names></name>, <etal>et al</etal></person-group>
<article-title>Renal involvement in a large cohort of Chinese patients with Castleman disease</article-title>. <source>Nephrol Dial Transplant</source>
<year>2012</year>;<volume>27</volume>:<fpage>iii119</fpage>&#x02013;<lpage>25</lpage>. <pub-id pub-id-type="doi">10.1093/ndt/gfr245</pub-id>
<pub-id pub-id-type="pmid">21602182</pub-id></mixed-citation></ref><ref id="R13"><label>13</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Nakamori</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Akagaki</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Yamaguchi</surname><given-names>Y</given-names></name>, <etal>et al</etal></person-group>
<article-title>Nephrotic syndrome with thrombocytopenia, lymphadenopathy, systemic inflammation, and splenomegaly</article-title>. <source>Intern. Med.</source>
<year>2018</year>;<volume>57</volume>:<fpage>1123</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.2169/internalmedicine.9556-17</pub-id>
<pub-id pub-id-type="pmid">29269660</pub-id></mixed-citation></ref><ref id="R14"><label>14</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Yuan</surname><given-names>X-G</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>F-F</given-names></name>, <etal>et al</etal></person-group>
<article-title>Renal complications of Castleman&#x02019;s disease: report of two cases and analysis of 75 cases</article-title>. <source>Clin Exp Nephrol</source>
<year>2011</year>;<volume>15</volume>:<fpage>921</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1007/s10157-011-0499-9</pub-id>
<pub-id pub-id-type="pmid">21822592</pub-id></mixed-citation></ref><ref id="R15"><label>15</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Seida</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Wada</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Morita</surname><given-names>Y</given-names></name>, <etal>et al</etal></person-group>
<article-title>Multicentric Castleman's disease associated with glomerular microangiopathy and MPGN-like lesion: does vascular endothelial cell-derived growth factor play causative or protective roles in renal injury?</article-title>
<source>Am J Kidney Dis</source>
<year>2004</year>;<volume>43</volume>:<fpage>e1.1</fpage>&#x02013;<lpage>e1.7</lpage>. <pub-id pub-id-type="doi">10.1053/j.ajkd.2003.09.023</pub-id>
<pub-id pub-id-type="pmid">15168420</pub-id></mixed-citation></ref><ref id="R16"><label>16</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Mizuno</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Sekine</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Oguro</surname><given-names>M</given-names></name>, <etal>et al</etal></person-group>
<article-title>Renal histology in a patient with TAFRO syndrome: a case report</article-title>. <source>Hum Pathol</source>
<year>2018</year>;<volume>82</volume>:<fpage>258</fpage>&#x02013;<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1016/j.humpath.2018.03.021</pub-id>
<pub-id pub-id-type="pmid">29626596</pub-id></mixed-citation></ref><ref id="R17"><label>17</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Nishimoto</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Kanakura</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Aozasa</surname><given-names>K</given-names></name>, <etal>et al</etal></person-group>
<article-title>Humanized anti&#x02013;interleukin-6 receptor antibody treatment of multicentric Castleman disease</article-title>. <source>Blood</source>
<year>2005</year>;<volume>106</volume>:<fpage>2627</fpage>&#x02013;<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2004-12-4602</pub-id>
<pub-id pub-id-type="pmid">15998837</pub-id></mixed-citation></ref><ref id="R18"><label>18</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Yoshizaki</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Murayama</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Ito</surname><given-names>H</given-names></name>, <etal>et al</etal></person-group>
<article-title>The role of interleukin-6 in Castleman disease</article-title>. <source>Hematol Oncol Clin North Am</source>
<year>2018</year>;<volume>32</volume>:<fpage>23</fpage>&#x02013;<lpage>36</lpage>. <pub-id pub-id-type="doi">10.1016/j.hoc.2017.09.003</pub-id>
<pub-id pub-id-type="pmid">29157617</pub-id></mixed-citation></ref><ref id="R19"><label>19</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Sui</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>D</given-names></name></person-group>
<article-title>Report of six kidney disease-associated Castleman's disease cases</article-title>. <source>Clin Nephrol</source>
<year>2015</year>;<volume>84</volume>:<fpage>344</fpage>&#x02013;<lpage>52</lpage>. <pub-id pub-id-type="doi">10.5414/CN108621</pub-id>
<pub-id pub-id-type="pmid">26445003</pub-id></mixed-citation></ref><ref id="R20"><label>20</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Perfetti</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Bellotti</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Maggi</surname><given-names>A</given-names></name>, <etal>et al</etal></person-group>
<article-title>Reversal of nephrotic syndrome due to reactive amyloidosis (AA-type) after excision of localized Castleman's disease</article-title>. <source>Am J Hematol</source>
<year>1994</year>;<volume>46</volume>:<fpage>189</fpage>&#x02013;<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1002/ajh.2830460306</pub-id>
<pub-id pub-id-type="pmid">7910717</pub-id></mixed-citation></ref><ref id="R21"><label>21</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Ikeda</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Chisuwa</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Kawasaki</surname><given-names>S</given-names></name>, <etal>et al</etal></person-group>
<article-title>Systemic reactive amyloidosis associated with Castleman's disease: serial changes of the concentrations of acute phase serum amyloid A and interleukin 6 in serum</article-title>. <source>J Clin Pathol</source>
<year>1997</year>;<volume>50</volume>:<fpage>965</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1136/jcp.50.11.965</pub-id>
<pub-id pub-id-type="pmid">9462253</pub-id></mixed-citation></ref><ref id="R22"><label>22</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>van Rhee</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Voorhees</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Dispenzieri</surname><given-names>A</given-names></name>, <etal>et al</etal></person-group>
<article-title>International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease</article-title>. <source>Blood</source>
<year>2018</year>;<volume>132</volume>:<fpage>2115</fpage>&#x02013;<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2018-07-862334</pub-id>
<pub-id pub-id-type="pmid">30181172</pub-id></mixed-citation></ref><ref id="R23"><label>23</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Tu</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Cortes</surname><given-names>J</given-names></name>, <etal>et al</etal></person-group>
<article-title>Clinical and pathological characteristics of HIV- and HHV-8&#x02013;negative Castleman disease</article-title>. <source>Blood</source>
<year>2017</year>;<volume>129</volume>:<fpage>1658</fpage>&#x02013;<lpage>68</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2016-11-748855</pub-id>
<pub-id pub-id-type="pmid">28100459</pub-id></mixed-citation></ref></ref-list></back></article>